Bio-Techne Corp (TECH)
77.11
+1.51
(+2.00%)
USD |
NASDAQ |
May 03, 09:36
Bio-Techne 1 Year Total Returns (Daily): -5.30% for May 2, 2024
1 Year Total Returns (Daily) Chart
Historical 1 Year Total Returns (Daily) Data
Date | Value |
---|---|
May 02, 2024 | -5.30% |
May 01, 2024 | -6.86% |
April 30, 2024 | -20.51% |
April 29, 2024 | -18.87% |
April 26, 2024 | -17.93% |
April 25, 2024 | -20.05% |
April 24, 2024 | -24.13% |
April 23, 2024 | -23.35% |
April 22, 2024 | -24.42% |
April 19, 2024 | -26.57% |
April 18, 2024 | -25.89% |
April 17, 2024 | -26.06% |
April 16, 2024 | -24.56% |
April 15, 2024 | -22.78% |
April 12, 2024 | -17.46% |
April 11, 2024 | -11.15% |
April 10, 2024 | -7.13% |
April 09, 2024 | -5.41% |
April 08, 2024 | -9.41% |
April 05, 2024 | -9.11% |
April 04, 2024 | -8.73% |
April 03, 2024 | -7.56% |
April 02, 2024 | -6.90% |
April 01, 2024 | -6.02% |
March 28, 2024 | -1.27% |
Date | Value |
---|---|
March 27, 2024 | -5.00% |
March 26, 2024 | -5.28% |
March 25, 2024 | -4.14% |
March 22, 2024 | -0.86% |
March 21, 2024 | -1.61% |
March 20, 2024 | -0.48% |
March 19, 2024 | -1.70% |
March 18, 2024 | -0.14% |
March 15, 2024 | 0.11% |
March 14, 2024 | -2.35% |
March 13, 2024 | 1.39% |
March 12, 2024 | 3.46% |
March 11, 2024 | 4.87% |
March 08, 2024 | 3.89% |
March 07, 2024 | 3.30% |
March 06, 2024 | -2.46% |
March 05, 2024 | -5.76% |
March 04, 2024 | -3.86% |
March 01, 2024 | -0.25% |
February 29, 2024 | 1.74% |
February 28, 2024 | 2.88% |
February 27, 2024 | 1.19% |
February 26, 2024 | -0.33% |
February 23, 2024 | -3.13% |
February 22, 2024 | -2.90% |
Total Return Definition
The Total return is the change in price over a specific period of time that includes dividends and distributions paid.
1 Year Total Returns (Daily) Range, Past 5 Years
-46.00%
Minimum
Sep 26 2022
142.0%
Maximum
Mar 16 2021
17.97%
Average
9.12%
Median
Apr 06 2022
1 Year Total Returns (Daily) Benchmarks
Agenus Inc | -55.53% |
BioCryst Pharmaceuticals Inc | -39.21% |
AIM ImmunoTech Inc | -16.66% |
Protalix BioTherapeutics Inc | -56.06% |
Armata Pharmaceuticals Inc | 65.23% |